December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

4.988 +0.028 (+0.56%)
Streaming Delayed Price Updated: 11:43 AM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Alvotech's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
From Alvotech
Via GlobeNewswire
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Alvotech's Earnings Outlook ↗
 
Via Benzinga
News headline image
Why Is Alvotech Stock Trading Higher On Wednesday? ↗
Alvotech acquires Swiss packaging firm Ivers-Lee to boost biosimilar production capacity ahead of three 2025 launches. 
Via Benzinga
News headline image
Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2025 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
From Alvotech
Via GlobeNewswire
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
From Alvotech
Via GlobeNewswire
News headline image
Why Is Teva Stock Trading Higher On Tuesday? ↗
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
News headline image
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
From Alvotech
Via GlobeNewswire
News headline image
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
From Alvotech
Via GlobeNewswire
News headline image
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? ↗
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
News headline image
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
From Alvotech
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.